Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators

Mol Carcinog. 1996 Nov;17(3):151-9. doi: 10.1002/(SICI)1098-2744(199611)17:3<151::AID-MC7>3.0.CO;2-I.


Uterine leiomyoma is the most frequent gynecologic neoplasm in women. By using a panel of cell lines derived from spontaneous Eker rat leiomyomas, we examined the estrogen-responsive phenotype of these tumor cells. Leiomyoma-derived ELT cell lines proliferated in response to estrogen, and estrogen-induced cell proliferation could be inhibited by the estrogen antagonist ICI 182780 and the selective estrogen-receptor modulators (SERMs) raloxifene and tamoxifen. In addition to inhibiting cell growth, these antagonists also inhibited estrogen-induced increases in progesterone-receptor expression. These data indicate that SERMs such as raloxifene and tamoxifen act as estrogen antagonists in uterine myometrial cells and suggest that this class of compounds may be effective for treatment of this important gynecologic neoplasm.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Cell Division / drug effects
  • Estradiol / analogs & derivatives
  • Estradiol / pharmacology*
  • Estrogen Antagonists / pharmacology*
  • Female
  • Fulvestrant
  • Leiomyoma / drug therapy*
  • Leiomyoma / pathology
  • Leiomyoma / ultrastructure*
  • Phenotype
  • Piperidines / pharmacology
  • Raloxifene Hydrochloride
  • Rats
  • Receptors, Estrogen / antagonists & inhibitors
  • Receptors, Estrogen / drug effects*
  • Receptors, Estrogen / metabolism
  • Tamoxifen / pharmacology
  • Tumor Cells, Cultured
  • Uterine Neoplasms / drug therapy*
  • Uterine Neoplasms / pathology
  • Uterine Neoplasms / ultrastructure*


  • Estrogen Antagonists
  • Piperidines
  • Receptors, Estrogen
  • Tamoxifen
  • Fulvestrant
  • Raloxifene Hydrochloride
  • Estradiol